替吉奥治疗中晚期胃癌患者的临床疗效及对血清sICAM-1、Survivin、CEA、CA199的影响  

Clinical efficacy and serum sICAM-1,Survivin,CEA and CA199 of treatment of patients with middle and advanced gastric cancer

作　　者：常英英 郭克锋 王坤[1] 刘红丽[1] 薛艳萍 高慧芳 CHANG Ying-ying;GUO Ke-f eng;WANG Kun;L IU Hong-li;XUE Yan-ping;GAO Hui-fang(Department of Laboratory,Sanmenxia the Yellow River Hospital,Sanmenxia 472000,China)

机构地区：[1]三门峡黄河医院检验科,河南三门峡472000

出　　处：《中国中西医结合消化杂志》2018年第8期691-694,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]探讨替吉奥治疗中晚期胃癌患者的临床疗效,检测血清可溶性细胞间黏附分子-1(sICAM-1)、细胞凋亡抑制蛋白存活素(Survivin)、癌胚抗原(CEA)、糖类抗原199(CA199)水平的变化,分析其作用机制和临床意义。[方法]选择我院2016年1月~2017年9月中晚期胃癌患者76例,随机分为对照组和研究组,各38例,对照组进行常规治疗,研究组应用替吉奥治疗。观察临床疗效及不良反应,并检测治疗前后血清sICAM-1、Survivin、CEA、CA199水平。[结果]研究组患者肿瘤控制率为97.37%(37/38),高于对照组86.84%(33/38),差异有统计学意义(P<0.05);研究组患者不良反应总发生率为42.11%(16/38),低于对照组57.89%(24/38),差异有统计学意义(P<0.05);治疗后研究组患者血清Survivin、sICAM-1、CEA和CA199分别为(306.48±36.79)pg/ml、(429.56±48.90)ng/ml、(26.42±3.88)ng/ml、(51.34±8.15)U/L,均低于对照组(412.75±35.83)pg/ml、(608.44±52.65)ng/ml、(32.53±4.51)ng/ml、(60.24±8.05)U/L,差异有统计学意义(P<0.05)。[结论]替吉奥治疗中晚期胃癌患者的临床疗效较好,能够显著降低不良反应,血清Survivin、sVCAM-1、CEA和CA199水平显著下调。[Objective]To explore the clinical efficacy of Teggio for the treatment of patients with advanced gastric cancer,and to detect the changes of Soluble intercellular adhesion molecule-1（sICAM-1）,Apoptosis inhibitory protein（Survivin）,Carcinoembryonic antigen（CEA）,Carbohydrate antigen 199（CA199）levels,and to analyze its mechanism of action and clinical significance.[Methods]76 patients with advanced gastric cancer from January in 2016 to September in 2017 in hospital were selected and randomly divided into control group and study group,38 patients in each group.Control group received routine treatment.Study group applied the treatment of Teggio.The clinical efficacy and adverse reactions were observed,and the serum levels of sICAM-1,Survivin,CEAand CA199 were detected before and after treatment.[Results]The tumor control rate of the study group was 97.37%（37/38）,which was higher than that of the control group 86.84%（33/38）,the difference was statistically significant（P〈0.05）.The total incidence of adverse reactions of the study group was 42.11%（16/38）,lower than the control group 57.89%（24/38）,the difference was statistically significant（P〈0.05）.After treatment,serum Survivin,sICAM-1,CEA and CA199 of the study group were（306.48±36.79）pg/ml,（429.56±48.90）ng/ml,（26.42±3.88）ng/ml,（51.34±8.15）U/L,respectively,all lower than the control group（412.75±35.83）pg/ml,（608.44±52.65）ng/ml,（32.53±4.51）ng/ml,（60.24±8.05）U/L,the difference was statistically signifi-cant（P〈0.05）.[Conclusion]Tiggio has a good clinical effect in the treatment of patients with advanced gastric cancer,which can significantly reduce adverse reactions,and the levels of serum Survivin,sVCAM-1,CEA and CA199 levels were significantly reduced.

关 键 词：替吉奥 胃癌 临床疗效 可溶性细胞间黏附分子-1 细胞凋亡抑制蛋白存活素 癌胚抗原 糖类抗原199 

分 类 号：R735.2[医药卫生—肿瘤]